Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity

Virology

Volumn 447, Issue 1-2, 2013, Pages 254-264

  Maruggi, Giulietta ^a   Shaw, Christine A ^a   Otten, Gillis R ^a   Mason, Peter W ^a   Beard, Clayton W ^a  

^a Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

5' UTR; Alphavirus replicon vaccine; Antigen expression; Attenuating mutation; Interferon induction; Secondary structure

Indexed keywords

ALPHAVIRUS REPLICON VACCINE; INTERFERON; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; IMMUNOGENICITY; IMMUNOREGULATION; INNATE IMMUNITY; INTERFERON INDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN STRUCTURE; REPLICON; SINDBIS VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS ATTENUATION; VIRUS GENOME; VIRUS MUTANT;

5′ UTR; ALPHAVIRUS REPLICON VACCINE; ANTIGEN EXPRESSION; ATTENUATING MUTATION; INTERFERON INDUCTION; SECONDARY STRUCTURE;

5' UNTRANSLATED REGIONS; ANIMALS; ANTIGENS; DRUG CARRIERS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; GENE EXPRESSION PROFILING; GENETIC VECTORS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; SINDBIS VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84885068221     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.07.021     Document Type: Article

References (39)

1. Alsharifi M., Lobigs M., Regner M., Lee E., Koskinen A., Mullbacher A. Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection. J. Immunol. 2005, 175:4635-4640.
2. Atkins G.J., Fleeton M.N., Sheahan B.J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev. Mol. Med. 2008, 10:e33.
3. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., Olmsted R.A., Hoeper A., Morris J., Negri S., Maughan M.F., Chulay J.D. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
4. Cruz C.C., Suthar M.S., Montgomery S.A., Shabman R., Simmons J., Johnston R.E., Morrison T.E., Heise M.T. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology 2010, 399:1-10.
5. Dubensky T.W., Driver D.A., Polo J.M., Belli B.A., Latham E.M., Ibanez C.E., Chada S., Brumm D., Banks T.A., Mento S.J., Jolly D.J., Chang S.M. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 1996, 70:508-519.
6. Fink K., Lang K.S., Manjarrez-Orduno N., Junt T., Senn B.M., Holdener M., Akira S., Zinkernagel R.M., Hengartner H. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur. J. Immunol. 2006, 36:2094-2105.
7. Frolov I., Hardy R., Rice C.M. Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. RNA 2001, 7:1638-1651.
8. Gardner J.P., Frolov I., Perri S., Ji Y., MacKichan M.L., zur Megede J., Chen M., Belli B.A., Driver D.A., Sherrill S., Greer C.E., Otten G.R., Barnett S.W., Liu M.A., Dubensky T.W., Polo J.M. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 2000, 74:11849-11857.
9. Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., Cu Y., Beard C.W., Brito L.A., Krucker T., O'Hagan D.T., Singh M., Mason P.W., Valiante N.M., Dormitzer P.R., Barnett S.W., Rappuoli R., Ulmer J.B., Mandl C.W. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:14604-14609.
10. Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R.A., Diamond, M.S., Colonna, M., 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proceedings of the National Academy of Sciences of the United States of America 103, 8459-8464.
11. Gorchakov R., Hardy R., Rice C.M., Frolov I. Selection of Functional 5' cis-Acting Elements Promoting Efficient Sindbis Virus Genome Replication. J. Virol. 2003, 78:61-75.
12. Heise M.T., White L.J., Simpson D.A., Leonard C., Bernard K.A., Meeker R.B., Johnston R.E. An Attenuating Mutation in nsP1 of the Sindbis-Group Virus S.A.AR86 Accelerates Nonstructural Protein Processing and Up-Regulates Viral 26S RNA Synthesis. J. Virol. 2003, 77:1149-1156.
13. Hidmark A.S., Nordstrom E.K., Dosenovic P., Forsell M.N., Liljestrom P., Karlsson Hedestam G.B. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J. Virol. 2006, 80:7100-7110.
14. Jaeger, J.A., Turner, D.H., Zuker, M., 1989. Improved predictions of secondary structures for RNA. Proceedings of the National Academy of Sciences of the United States of America 86, 7706-7710.
15. Kinney R.M., Chang G.J., Tsuchiya K.R., Sneider J.M., Roehrig J.T., Woodward T.M., Trent D.W. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. J. Virol. 1993, 67:1269-1277.
16. Kulasegaran-Shylini R., Atasheva S., Gorenstein D.G., Frolov I. Structural and functional elements of the promoter encoded by the 5' untranslated region of the Venezuelan equine encephalitis virus genome. J. Virol. 2009, 83:8327-8339.
17. Kulasegaran-Shylini R., Thiviyanathan V., Gorenstein D.G., Frolov I. The 5'UTR-specific mutation in VEEV TC-83 genome has a strong effect on RNA replication and subgenomic RNA synthesis, but not on translation of the encoded proteins. Virology 2009, 387:211-221.
18. Leitner W.W., Bergmann-Leitner E.S., Hwang L.N., Restifo N.P. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 2006, 24:5110-5118.
19. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., Dubensky T.W., Ying H., Restifo N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003, 9:33-39.
20. Lemm J.A., Rice C.M. Roles of nonstructural polyproteins and cleavage products in regulating Sindbis virus RNA replication and transcription. J. Virol. 1993, 67:1916-1926.
21. Lemm J.A., Rumenapf T., Strauss E.G., Strauss J.H., Rice C.M. Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis. EMBO J. 1994, 13:2925-2934.
22. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991, 9:1356-1361.
23. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 2000, 74:914-922.
24. Nishimoto K.P., Laust A.K., Wang K., Kamrud K.I., Hubby B., Smith J.F., Nelson E.L. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 2007, 20:88-104.
25. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., Romero R.E., Tang Z., Bin Q., Dubensky T.W., Vajdy M., Otten G.R., Polo J.M. An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector. J. Virol. 2003, 77:10394-10403.
26. Pichlmair A., Schulz O., Tan C.P., Rehwinkel J., Kato H., Takeuchi O., Akira S., Way M., Schiavo G., Reis e Sousa C. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 2009, 83:10761-10769.
27. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239:389-401.
28. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. J. Virol. 2002, 12:279-296.
29. Ryman K.D., Klimstra W.B. Host responses to alphavirus infection. Immunol. Rev. 2008, 225:27-45.
30. Ryman K.D., White L.J., Johnston R.E., Klimstra W.B. Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol. 2002, 15:53-76.
31. Simmons J.D., Wollish A.C., Heise M.T. A determinant of Sindbis virus neurovirulence enables efficient disruption of Jak/STAT signaling. J. Virol. 2010, 84:11429-11439.
32. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 1994, 58:491-562.
33. Thompson J.M., Whitmore A.C., Konopka J.L., Collier M.L., Richmond E.M., Davis N.L., Staats H.F., Johnston R.E. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3722-3727.
34. Thompson J.M., Whitmore A.C., Staats H.F., Johnston R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 2008, 26:4998-5003.
35. Thompson J.M., Whitmore A.C., Staats H.F., Johnston R.E. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 2008, 26:4267-4275.
36. Ulmer J.B., Mason P.W., Geall A., Mandl C.W. RNA-based vaccines. Vaccine 2012, 30:4414-4418.
37. van den Broek M.F., Muller U., Huang S., Aguet M., Zinkernagel R.M. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 1995, 69:4792-4796.
38. White L.J., Wang J.G., Davis N.L., Johnston R.E. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region. J. Virol. 2001, 75:3706-3718.
39. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., Huang H.V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989, 243:1188-1191.